Stocktoria
Inmune Bio, Inc. INMB
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2019-02-04
Inmune Bio, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $50,000 | $14,000 | $155,000 | $374,000 | $181,000 |
| R&D expense | $20.7M | $33.2M | $20.3M | $17.1M | $20.5M |
| Operating income | -$47.4M | -$42.6M | -$29.7M | -$26.0M | -$29.2M |
| Interest expense | — | $357,000 | $2.3M | $2.0M | — |
| Net income | -$45.9M | -$42.1M | -$30.0M | -$27.3M | -$30.3M |
| EPS (diluted) | $-1.86 | $-2.11 | $-1.67 | $-1.52 | $-1.88 |
| Operating cash flow | -$22.6M | -$33.4M | -$12.0M | -$22.7M | -$28.5M |
| Free cash flow | -$23.6M | — | — | — | — |
| Cash & equivalents | $24.8M | $20.9M | $35.8M | $52.2M | $74.8M |
| Total assets | $32.4M | $39.6M | $57.0M | $81.8M | $99.9M |
| Total liabilities | $8.8M | $7.5M | $18.9M | $21.7M | $19.7M |
| Shareholders' equity | $23.5M | $32.1M | $37.3M | $60.1M | $80.2M |
Source: SEC EDGAR filings · CIK 0001711754 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.